Life Sciences industry leader joins the region’s Life Science & Healthcare membership organisation
Cambridge, UK: 10 April 2024
This December, we invite our customers and prospective partners to join Catalent for an exclusive open house in Swindon during England’s most enchanting season. As the streets sparkle with festive lights and holiday spirit, you’ll step into a rare opportunity to see how Zydis® ODT, the world’s leading orally disintegrating tablet technology, continues to transform patient-centric drug delivery.
IP education session by Stratagem: IP for Start- ups and SMEs: Leveraging your IP strategy to drive business growth and unlock funding opportunities.
18th November – Glasshouse 4-6pm
For all spin-outs, startups and SMEs. Join Stratagem for an exclusive event at the Cambridge Glasshouse to learn more about how having a well thought out IP strategy which aligns with your business plan and goals will help drive growth and unlock funding opportunities. We will share thoughts about what Investors expect to see in early due diligence.
Partnership with Solve Scientific strengthens international sales as part of ongoing global expansion
By LimestoneGrey, Chartered Tax Advisers specialising in R&D tax relief
Many companies working within the Med-Tech and life sciences sectors are tackling global challenges such as antimicrobial resistance, ageing populations and chronic disease management. Addressing these complex issues often requires research that extends beyond the UK's borders.
By Tony Jones, CEO, One Nucleus
Time: 10 AM EST | December 11, 2025
Interferon-gamma (IFNγ) plays a paradoxical role in CAR-T therapy—it’s essential for antitumor activity but can also limit CAR-T expansion and persistence, especially in CD28-based designs.
Time: 10 AM EST | November 24, 2025
CAR-T therapy has achieved remarkable success in hematologic malignancies but faces major hurdles in solid tumors due to their immunosuppressive microenvironment. Angiogenesis, driven by the VEGF pathway, plays a critical role in fueling tumor growth and suppressing immune responses.
LONDON, UK & COPENHAGEN, Denmark – November 4, 2025 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for Vicore Pharma Holding AB (STO: VICO) and is pleased to announce the placement of Katrine Husum as R&D Senior Project Director.
Your group
The Cortes-Ciriano group studies the mutational processes and mechanisms of genome instability
underpinning tumourigenesis, immune escape, and drug response through the analysis of high-throughput sequencing data from clinical samples. The group is also leading the development of novel approaches for early cancer detection using long-read sequencing. More information about the group can be found here.
Your supervisor